Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...
Macrophages can alternate between two states: an inflammatory state for fighting infection and a non-inflammatory state for ...
14h
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback